NASDAQ:ORIC Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis $11.99 -0.04 (-0.33%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$12.00 +0.01 (+0.08%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Oric Pharmaceuticals Stock (NASDAQ:ORIC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oric Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.90▼$12.2950-Day Range$10.60▼$14.6552-Week Range$7.23▼$14.68Volume1.09 million shsAverage Volume1.66 million shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$20.67Consensus RatingModerate Buy Company Overview Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research is centered on mechanisms that enable tumors to resist or evade treatment, with the goal of restoring sensitivity to established cancer therapies and improving patient outcomes. Oric’s pipeline has included investigational small-molecule therapies designed to target cancer biology and treatment resistance. These programs include ORIC-533, an oral inhibitor of CD73 being studied in oncology, and ORIC-944, an oral allosteric inhibitor of EED, a component of the polycomb repressive complex 2. The company has also developed ORIC-114, a brain-penetrant investigational inhibitor directed at selected EGFR and HER2 alterations. Founded in 2014 and headquartered in South San Francisco, California, Oric Pharmaceuticals conducts research and clinical development activities through collaborations with academic institutions, clinical investigators and other biotechnology or pharmaceutical organizations. Its programs are intended for patients with solid tumors and hematologic malignancies, although the availability and status of specific candidates may change as clinical studies progress.AI Generated. May Contain Errors. Read More Oric Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreORIC MarketRank™: Oric Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 576th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingOric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOric Pharmaceuticals has a consensus price target of $20.67, representing about 72.4% upside from its current price of $11.99.Amount of Analyst CoverageOric Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Oric Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oric Pharmaceuticals are expected to decrease in the coming year, from ($1.53) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oric Pharmaceuticals is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oric Pharmaceuticals is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOric Pharmaceuticals has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oric Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted16.69% of the float of Oric Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOric Pharmaceuticals has a short interest ratio ("days to cover") of 9.85.Change versus previous monthShort interest in Oric Pharmaceuticals has recently decreased by 6.94%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOric Pharmaceuticals does not currently pay a dividend.Dividend GrowthOric Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.16 News SentimentOric Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Oric Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest3 people have searched for ORIC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Oric Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oric Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,243,532.00 in company stock.Percentage Held by Insiders5.70% of the stock of Oric Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oric Pharmaceuticals' insider trading history. Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oric Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORIC Stock News HeadlinesDoes ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?October 8 at 9:15 PM | finance.yahoo.comORIC(R) Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentOctober 6, 2026 | marketscreener.comMIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentOctober 5, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Rated "Outperform" in New Coverage at Leerink PartnersOctober 5, 2026 | americanbankingnews.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) Stock: Insider Dominic Piscitelli Sells 13,400 SharesOctober 1, 2026 | americanbankingnews.comOric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 13,400 Shares of Company StockSeptember 30, 2026 | insidertrades.comSee More Headlines ORIC Stock Analysis - Frequently Asked Questions How have ORIC shares performed this year? Oric Pharmaceuticals' stock was trading at $8.18 on January 1st, 2026. Since then, ORIC shares have increased by 46.6% and is now trading at $11.99. How were Oric Pharmaceuticals' earnings last quarter? Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its earnings results on Monday, August, 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. When did Oric Pharmaceuticals IPO? Oric Pharmaceuticals (ORIC) raised $112 million in an initial public offering on Friday, April 24th 2020. The company issued 7,500,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Oric Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oric Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST). Company Calendar Last Earnings8/03/2026Today10/09/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ORIC's financial health is in the Green zone, according to TradeSmith. ORIC has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ORIC CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees111Year Founded2014Price Target and Rating Average Price Target for Oric Pharmaceuticals$20.67 High Price Target$27.00 Low Price Target$14.00 Potential Upside/Downside+72.4%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$129.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.35% Return on Assets-33.39% Debt Debt-to-Equity RatioN/A Current Ratio13.19 Quick Ratio13.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book3.07Miscellaneous Outstanding Shares103,650,000Free Float97,745,000Market Cap$1.24 billion OptionableOptionable Beta0.99 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ORIC) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORIC Stock Alerts